Eagle Pharmaceuticals (EGRX): Notes From Management Meetings - RBC

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on Eagle Pharmaceuticals (NASDAQ: EGRX) after hosting two days of meetings with management.

Three key points include: 1) the pipeline is led by Ryanodex in EHS and ecstasy/meth

2) there is further "upside" from the bendamustine franchise

3) capital deployment remains a wildcard

The analyst believes EGRX has established a solid underlying cash flow base with upside to come from the pipeline, greater BENDEKA duration, and capital deployment. EPS for 2016-18E increases to $3.51, $4.31 and $5.39 and the price target goes to $80 from $78.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $64.95 yesterday.

You May Also Be Interested In

• Barclays Downgrades Dana Holding (DAN) to Equalweight
• Emkay Global Starts Vedanta Aluminium Metal (VAML:IN) at Buy (1)
• H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy